AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition (NYSE:ABBV)

Group 1 - The article discusses AbbVie (NYSE: ABBV) and its recent FDA approvals for Skyrizi and Rinvoq, which are expected to positively impact the company's performance following the patent loss of Humira [2] - The author operates the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and includes a model portfolio of small and mid-cap stocks [2] Group 2 - The article does not provide specific financial data or performance metrics related to AbbVie or the pharmaceutical industry [1][3][4]